Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

PartnershipHRS-1596Positive

AI Analysis

Summary

Novo and Hengrui Pharma entered an exclusive license agreement valued at $2.6 billion for HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist for obesity and diabetes treatment.

Outcome Details

Exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist

Importance:7/10

Sentiment:

0.70

GLP-1obesitydiabeteslicensingpartnershiporal formulation

Related Companies

$NVO

Read the original article

Published by GlobeNewswire Pharma on September 29, 2026 4:35 AM

Read Original